Please use this identifier to cite or link to this item:
Cardiac arrhythmias in patients with COVID‐19
Yueying Wang
Zhaojia Wang
Gary Tse
Lin Zhang
Elaine Y. Wan
Yutao Guo
Gregory Y. H. Lip
Guangping Li
Zhibing Lu
Tong Liu
Novel Coronavirus
Acceso Abierto
Angiotensin-converting enzyme-2
QT interval
The emergence of coronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has become a major global public health concern. Although SARS‐CoV‐2 causes primarily respiratory problems, concurrent cardiac injury cannot be ignored since it may be an independent predictor for adverse outcomes. Cardiac arrhythmias are often observed in patients with COVID‐19, especially in severe cases, and more likely contribute to the high risk of adverse outcomes. Arrhythmias should be regarded as one of the main complications of COVID‐19. Mechanistically, a number of ion channels can be adversely affected in COVID‐19, leading to alterations in cardiac conduction and/or repolarization properties, as well as calcium handling, which can predispose to cardiac arrhythmogenesis. In addition, several antimicrobials that are currently used as potential therapeutic agents for COVID‐19, such as chloroquine, hydroxychloroquine and azithromycin, have uncertain benefit, and yet may induce electrocardiographic QT prolongation with potential ventricular pro‐arrhythmic effects. Continuous electrocardiogram monitoring, accurate and prompt recognition of arrhythmias are important. The present review focuses on cardiac arrhythmias in patients with COVID‐19, its underlying mechanisms, and proposed preventive and therapeutic strategies.
Journal of Arrhythmia
Epidemia COVID-19
Versión publicada
publishedVersion - Versión publicada
Appears in Collections:Artículos científicos

Upload archives